Liver Toxicity Risk Management Should Consider Timing Of Signal, FDAer Says
Executive Summary
Risk management programs for drug-induced hepatotoxicity should take into account timing and level of exposure, FDA Office of Drug Safety Division of Drug Risk Evaluation Director Mark Avigan, MD, said